Summary & Overview
HCPCS C9025: Injection, ramucirumab, 5 mg
HCPCS Level II code C9025 identifies the drug product for ramucirumab, billed in 5 mg increments, and is used when reporting the supply of this targeted monoclonal antibody. Ramucirumab is an oncology biologic with applications in several cancer treatment regimens; accurate coding of the drug product is important for clinical documentation, claims processing, and national drug utilization tracking. This publication covers payer coverage patterns and benchmarks for major national payers, including Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code and its clinical context, an overview of typical sites of service where the drug is administered, and a summary of what to expect in payer coverage policies and reimbursement benchmarks. The analysis highlights common billing considerations for injectable oncology biologics, including unitization of dose reporting and implications for outpatient infusion billing. Where available, the publication includes payer-specific coverage notes, prior authorization tendencies, and national reimbursement benchmarks for C9025. Data not available in the input will be explicitly marked as such in the relevant sections.
Billing Code Overview
HCPCS Level II code C9025 represents injection, ramucirumab, 5 mg. This code denotes administration of the monoclonal antibody ramucirumab in 5 mg units and is used to report the drug product for billing purposes.
-
Service type: Intravenous or injectable biologic drug administration (drug supply)
-
Typical site of service: Outpatient infusion center or hospital outpatient department
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with advanced or metastatic solid tumor disease (commonly gastric, gastroesophageal junction adenocarcinoma, or colorectal cancer) receiving targeted monoclonal antibody therapy. The service is administration of C9025 (injection, ramucirumab, 5 mg) provided in an outpatient infusion center, oncology clinic, or hospital outpatient department. The clinical workflow: patient arrives for a scheduled infusion, nurse performs pre-infusion assessment including vital signs, review of recent labs (especially liver function and blood counts), verifies prescription and dose, prepares ramucirumab vials or syringe per oncology pharmacy, obtains IV access, administers premedication if indicated, infuses ramucirumab per protocol over the recommended infusion time while monitoring for infusion reactions, documents medication lot, dose, and patient response, and schedules follow-up oncology visits and subsequent cycles. Typical documentation includes indication, dosage calculation, lot number, infusion start and stop times, infusion site, any reactions and interventions, and payer/authorization information. Supportive services such as antiemetics or growth factors may be billed separately according to payer policies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a same-day, unrelated or distinct E/M is performed in addition to administration of . |